Click on image to view larger version.

Figure 1 Primary End Point According to Treatment and KIF6 719Arg Carrier Status

Kaplan-Meier estimates of the cumulative incidence of death or major cardiovascular events in the high-dose atorvastatin and standard-dose pravastatin treatment groups: (A) among carriers of the KIF6 719Arg variant; (B) among noncarriers of the KIF6 719Arg variant. The log-rank p values are based on 2 years of follow-up. The unadjusted hazard ratios (HR) and 95% confidence intervals (CI) are based on 30 months of follow-up.